PMID- 17766143
OWN - NLM
STAT- MEDLINE
DCOM- 20080513
LR  - 20220309
IS  - 1040-8428 (Print)
IS  - 1040-8428 (Linking)
VI  - 66
IP  - 1
DP  - 2008 Apr
TI  - Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: 
      accumulating evidence of efficacy, synergy and safety.
PG  - 31-41
AB  - Neoadjuvant chemotherapy is used in non-metastatic breast cancer in order to 
      eradicate micrometastatic deposits early during disease course, as well as in 
      order to decrease tumour bulk and render surgery feasible or breast-conserving. 
      Moreover, it offers promise to serve as an in vivo chemosensitivity assay and as 
      a powerful predictive factor for outcome. Trastuzumab, a monoclonal antibody 
      targeting an epitope in the extracellular domain of the Human Epidermal Growth 
      Factor Receptor-2 (HER2/erbB-2), was found to be active in HER2-overexpressing 
      metastatic as well as in resected breast cancer when given post-operatively. In 
      this review, we summarise the evidence on the activity and safety of 
      trastuzumab-containing neoadjuvant chemotherapy for the management of women with 
      localised, irresectable or resectable breast cancer. Twenty-three published 
      studies enrolling a total of 585 patients reported pathologic complete responses 
      (pCR) ranging from 7 to 78% with a favourable adverse event profile, data that 
      are presented and discussed in this review. The impact of trastuzumab on 
      long-term outcome, the identification of surrogate biomarkers for sensitivity or 
      resistance to antineoplastic therapy, the optimal schedule of trastuzumab 
      administration and the more active chemotherapeutic regimen for synergism are 
      only a few of the key points needing elucidation so as to rationalise 
      trastuzumab-based approaches.
FAU - Lazaridis, George
AU  - Lazaridis G
AD  - Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, 
      45500 Ioannina, Greece.
FAU - Pentheroudakis, George
AU  - Pentheroudakis G
FAU - Pavlidis, Nicholas
AU  - Pavlidis N
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20070904
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Breast Neoplasms/chemistry/*drug therapy
MH  - Clinical Trials as Topic
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Receptor, ErbB-2/analysis
MH  - Trastuzumab
RF  - 75
EDAT- 2007/09/04 09:00
MHDA- 2008/05/14 09:00
CRDT- 2007/09/04 09:00
PHST- 2007/04/19 00:00 [received]
PHST- 2007/07/07 00:00 [revised]
PHST- 2007/07/24 00:00 [accepted]
PHST- 2007/09/04 09:00 [pubmed]
PHST- 2008/05/14 09:00 [medline]
PHST- 2007/09/04 09:00 [entrez]
AID - S1040-8428(07)00157-6 [pii]
AID - 10.1016/j.critrevonc.2007.07.002 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2008 Apr;66(1):31-41. doi: 
      10.1016/j.critrevonc.2007.07.002. Epub 2007 Sep 4.